Gelonghui, May 17 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that currently the company has not carried out TMA research, and in terms of technology, it can be produced using an enzymatic catalytic process in terms of synthesis.
金城医药(300233.SZ)：未开展TMA的研究
Jincheng Pharmaceutical (300233.SZ): No TMA studies have been conducted
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.